Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.
about
Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patientsExtended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks for patients with chronic hepatitis C virus genotype 1 infection having shown slow antiviral responseImproved COBAS TaqMan Hepatitis C Virus Test (Version 2.0) for Use with the High Pure System: Enhanced Genotype Inclusivity and Performance Characteristics in a Multisite StudyManagement of hepatitis c genotype 4 in the liver transplant settingKASL clinical practice guidelines: management of hepatitis CHepatitis C virus genotype 6: virology, epidemiology, genetic variation and clinical implicationResponse Prediction and Treatment Tailoring for Chronic Hepatitis C Virus Genotype 1 InfectionDifferences between Two Real-Time PCR-Based Hepatitis C Virus (HCV) Assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and One Signal Amplification Assay (Versant HCV RNA 3.0) for RNA Detection and QuantificationAbbott RealTime Hepatitis C Virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV Assays for Prediction of Sustained Virological Response to Pegylated Interferon and Ribavirin in Chronic Hepatitis C PatientsPerformance of the Abbott Real-Time PCR Assay Using m2000sp and m2000rt for Hepatitis C Virus RNA QuantificationSustained virological response based on rapid virological response in genotype-3 chronic hepatitis C treated with standard interferon in the Pakistani populationExpert opinion on the treatment of patients with chronic hepatitis CRate of Sustained Virologic Response in Relation to Baseline Hepatitis C Virus (HCV) RNA Level and Rapid Virologic Clearance in Persons with Acute HCV InfectionOn-treatment predictions of success in peg-interferon/ribavirin treatment using a novel formulaFactors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C populationImmediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis CBenefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort StudyDiagnosis, management, and treatment of hepatitis C: an updateStudy of PKRBD in HCV genotype 3a infected patients in response to interferon therapy in Pakistani population.Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agentsHCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscapeIndividualisation of antiviral therapy for chronic hepatitis C.Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis.Optimizing the dose and duration of therapy for chronic hepatitis C.IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infectionTreatment options for HCV nonresponders and relapse patients.Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations.New antiviral therapies for chronic hepatitis CEvolution of interferon-based therapy for chronic hepatitis C.Twenty four-week peginterferon plus ribavirin after interferon-β induction for genotype 1b chronic hepatitis C.Predicting the probable outcome of treatment in HCV patients.Peginterferon and ribavirin treatment for hepatitis C virus infectionRevisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin.Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population.Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users.Efficacy of 24-week pegylated interferon alpha and ribavirin combination therapy in highly selected patients infected with hepatitis C virus genotype 1.Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease.HBV and HCV therapy.Challenging clinical cases in HCV infection.
P2860
Q24200534-3D2B3356-CBA6-4EDA-8D77-02EE6D3F3A16Q24235606-2E7BC356-2505-4A09-BFD9-2A76E42F44F0Q24289102-543A5637-406B-4E09-A966-E61C736CF62BQ26749326-79DDD5CD-2C46-44D7-855C-09D33B7A68BDQ26752471-1C7EEE7B-1FE6-4B16-8A92-C05432F92CCDQ27024231-E7118550-9BCC-4982-BA77-4F5A14EC76EAQ27481003-A60EC316-1301-40BD-978E-E9DC40659857Q27487396-B0D9267C-83CE-4818-A58C-F22B4B8637CAQ27487942-FF40BE37-2936-4937-B8B2-ED590CAA5C2AQ27488563-CFA14F35-EE48-45B7-ACDC-4E4F03C04CF9Q27488860-B8EF61C9-43CC-46BA-893E-C1312445FEFAQ27489903-41D1EA63-3FF3-4A54-889E-8B98BCE30BC0Q27490171-B9F997E2-1D37-4EF1-A953-2FE2479094FBQ27490760-30678471-B577-4100-80C9-15BFC6D87F5FQ27490831-D1F5E7B0-59A3-4B47-A324-733406FE37BCQ27491312-552AF65B-B0DA-4773-8B74-46065A77DB8CQ28546936-59DBA873-0D04-458A-942D-36776A4EA69CQ29619682-C4B1A1A6-BDAD-4EA3-9CB4-601EF89B0B7DQ30356602-ACAB211D-786B-497C-ABA8-ADE141D90D64Q30365599-8A7C82DC-178D-4643-B6AE-D2B9BBFB01B7Q31012317-A544B979-CE28-42F0-87DD-BC4EFEF73D8CQ33390478-02FFFE55-8DB0-4416-B058-8088FF52FFE6Q33559298-91351941-09A1-468F-9EF7-7B0E8099BDC9Q33803007-27461466-E156-48BB-B817-9DDE554EEB3BQ33855483-5630AB3F-9F1C-49AF-87F5-12F1C52F2D93Q33867243-57C5D3F8-7C0C-4A58-8AA9-40937DBD89D1Q33916357-46F24F14-98DD-4591-84DB-1E6B625DECD1Q34087387-2A9354D6-C308-456F-A21C-AF19C422E5F5Q34130399-640B031D-4EC5-4D73-94CE-6DF6FCD47388Q34342092-CF56E1AC-3220-4B0A-A2B7-BBD5B20706FAQ34390274-0246C8BC-A41E-4E5A-8641-272440C98D98Q34409039-174FCDB5-1CFE-4654-AB22-0E3AE25FCACFQ34521371-BD9BCF0E-E576-45D8-828D-B71D2DD18235Q34532854-41A69325-B73E-4A34-8D1D-39B177FC0F02Q34694441-FCD16A26-EAB0-40BF-95DA-8ED85FE30770Q35053344-9B50FBFC-9A24-4D4E-A8C7-3EC30685595BQ35089901-F53BA5B4-13AA-461D-A792-B48DB11AE5CBQ35237341-F1C3944C-9BC7-411A-8003-54DE82B34879Q35259824-50E1CD8C-6524-4529-8532-4AB2584C9517Q35263701-AC6608CE-5AF4-4269-B27A-418B143DB022
P2860
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Early identification of HCV ge ...... -2a (40 kd)/ribavirin therapy.
@en
Early identification of HCV ge ...... 4 weeks peginterferon alpha-2a
@nl
type
label
Early identification of HCV ge ...... -2a (40 kd)/ribavirin therapy.
@en
Early identification of HCV ge ...... 4 weeks peginterferon alpha-2a
@nl
prefLabel
Early identification of HCV ge ...... -2a (40 kd)/ribavirin therapy.
@en
Early identification of HCV ge ...... 4 weeks peginterferon alpha-2a
@nl
P2093
P356
P1433
P1476
Early identification of HCV ge ...... -2a (40 kd)/ribavirin therapy.
@en
P2093
Andrew M Ackrill
Bernard Willems
Donald M Jensen
Patrick Marcellin
Paul J Pockros
Peter Ferenci
Stephanos J Hadziyannis
Timothy R Morgan
P304
P356
10.1002/HEP.21159
P407
P577
2006-05-01T00:00:00Z